AIOSYN
Aiosyn, a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney disease, announced the introduction of its NephroPath platform. By partnering with Aiosyn, CROs, biopharma, and researchers can accelerate the development of Chronic Kidney Disease (CKD) therapies using new and quantitative insights offered through Nephropath’s Kidney Image Analysis Services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240228760007/en/
Figure 1. Illustration of the NephroPath platform’s capabilities in performing automated quantification and multi-class prediction on an entire rat kidney cortex. Notable classes: normal tubuli (orange), atrophic/dilated tubuli (green/red), glomeruli (pink), abnormal/sclerotic glomeruli (dark blue), arteries (light blue), interstitium (not colored). (Photo: Business Wire)
The NephroPath platform provides computational pathology algorithms for a detailed evaluation of histological biomarkers in kidney biopsies, including segmentation of main tissue classes, quantification of interstitial fibrosis, precise localization and quantification of glomeruli, and more. These AI-powered analyses effectively overcome the constraints of current semi-quantitative scoring systems, which are often based on subregions of the kidney and are subject to observer variability.
NephroPath’s AI-based quantification provides reproducible, consistent, fast, and more detailed scoring of renal pathology (imaging) biomarkers in preclinical and clinical specimens* compared to human reading. This can accelerate preclinical and clinical development projects. The algorithms will also be instrumental in new CKD biomarker discovery projects.
Through Nephropath’s Kidney Image Analysis Services, Aiosyn offers whole kidney quantification and custom kidney analyses. Aiosyn’s data-rich analysis derived from slide data provides per-slide tissue quantifications and detailed dataset characterization. Findings are delivered in a comprehensive image analysis report, including biomarker scores and visual results.
“Using Aiosyn's NephroPath platform we provide researchers with a new and powerful technique to complement the CKD drug development toolbox,” said Patrick de Boer, CEO of Aiosyn.
CKD is forecasted to grow to the fifth predominant cause of mortality by 2040 (1), and with over 90+ new CKD therapies in development, there is a need for advanced tools that can accelerate drug development and enhance diagnostic accuracy.
In a recent preclinical study, conducted in collaboration with a leading preclinical research organization (CRO), the NephroPath platform demonstrated its effectiveness in segmenting kidney tissue classes (Figure 1) and quantifying glomerulosclerosis and tubular damage on whole rat kidneys. A positive correlation was observed between the glomerulosclerosis and tubular scores and kidney damage across all groups (the study abstract will be presented at the upcoming CKD Summit in Boston from March 19-21).
To learn more about the NephroPath platform and to explore potential collaboration, request a demo with our team.
About Aiosyn
Aiosyn is a Dutch company that develops precision pathology software for cancer and kidney disease. Aiosyn’s solutions are integrated into standard pathology workflows. The Aiosyn team has been built upon more than 20 years of research experience in the field of pathology and is rooted in the pathology practice.
*For scientific validity only. The NephroPath platform is for Research Use Only and should not be used for diagnostic procedures.
Sources
- Foreman, K. J., Marquez, N., Dolgert, A., Fukutaki, K., Fullman, N., McGaughey, M., … & Murray, C. J. (2018). Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. The Lancet, 392(10159), 2052-2090.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228760007/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Reports Third Quarter 2025 Results4.11.2025 23:12:00 CET | Press release
Reaffirms Full Year 2025 Financial Guidance IFF (NYSE: IFF) reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Consolidated Summary: Management Commentary “Our third quarter results demonstrate continued execution in a tough operating environment,” said Erik Fyrwald, CEO of IFF. “Sales momentum in Scent and Taste remain solid, supported by strong new win contributions. This performance helped offset short-term pressures in Health and Biosciences - which we are addressing by strengthening our innovation and commercial capabilities - and a sales reduction in Food Ingredients as we focus on driving higher margins.” “Profitability in the quarter improved high-single digits year-over-year, with margin expansion driven predominantly by productivity. By maintaining a disciplined focus on operational excellence, we are driving sustained profitability while investing in IFF for long-term success.” “In a more challenging environment, we’re doing what we
The Estée Lauder Companies Announces Secondary Offering of Class A Common Stock by Selling Stockholders4.11.2025 22:47:00 CET | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announces that trusts affiliated with descendants of Leonard A. Lauder (the “Selling Stockholders”) propose to sell 11,301,323 shares of the Company’s Class A Common Stock, par value $.01 per share, through a proposed registered public offering (the “Offering”). The Selling Stockholders will receive all of the proceeds from the Offering. The Company is not selling any shares of Class A Common Stock in the Offering and will not receive any proceeds from the Offering. The Selling Stockholders intend to use the proceeds of the Offering to assist with the settlement of Leonard A. Lauder’s estate, including to satisfy certain estate obligations such as estate taxes, debts and administration expenses. Based on shares outstanding as of October 23, 2025, following completion of the offering, members of the Lauder family will beneficially own, directly or indirectly, 82% of the outstanding voting power of the Company’s Common Stock. The Selling S
New Global Survey Reveals Oracle Database Customers are Evolving their Database Strategies Citing High Costs, Support Challenges and Need for Advanced AI/ML Capabilities4.11.2025 21:43:00 CET | Press release
Third-party support provides Oracle Database customers with significant cost savings and premium support, allowing organizations to focus their resources toward AI/ML and LLM initiatives Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the findings of the 2025 Database Strategies and Support Survey – The Diversification and Decentralization Revolution, a global study conducted by Unisphere Research of more than 200 Oracle Database managers and practitioners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104640087/en/ New Global Survey Reveals Oracle Database Customers are Evolving their Database Strategies Citing High Costs, Support Challenges and Need for Advanced AI/ML Capabilities Oracle Database Customers Face Suppor
TRU Simulation receives Japanese Civil Aviation Bureau qualification for the SUBARU Bell 412EPX Flight Training Device, delivering next-level realism to rotorcraft training operators in Japan4.11.2025 21:30:00 CET | Press release
TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Bell Textron Inc., today announced the SUBARU Bell 412EPX Flight Training Device (FTD) has received Level 5 qualification from the Japanese Civil Aviation Bureau (JCAB), marking a significant milestone in advancing rotorcraft training capabilities in Japan. Developed in collaboration with Bell, the FTD supports SUBARU’s mission in civil aviation by enabling pilots to train for a wide range of operations—from routine transport to complex search and rescue (SAR) missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104983178/en/ TRU Simulation receives Japanese Civil Aviation Bureau qualification for the SUBARU Bell 412EPX Flight Training Device, delivering next-level realism to rotorcraft training operators in Japan “SUBARU pilots flying some of Japan’s most critical missions now have access to immersive, high-fidelity training that b
PennAero and Tinicum Announce Acquisition of TriMas Aerospace4.11.2025 20:17:00 CET | Press release
Tinicum, L.P. (“Tinicum”) today announced that one of its affiliates has signed an agreement to acquire the aerospace assets of TriMas Corporation (“TriMas Aerospace”), through which TriMas Aerospace will be merged with PennAero, a Tinicum portfolio company (“the Transaction”). Funds managed by Blackstone will be a minority investor in the Transaction. This investment reinforces PennAero’s strategy of partnering with its customers to provide best-in-class engineering, manufacturing, customer service and support. TriMas Aerospace is a leading provider of highly engineered fasteners and precision-machined components for mission-critical applications across the global commercial aerospace and defense industries. Backed by a portfolio of trusted brands, including Monogram Aerospace Fasteners™, Allfast Fastening Systems®, Mac Fasteners™, TFI Aerospace, TriMas Aerospace Germany, Martinic Engineering™, RSA Engineered Products™ and Weldmac Manufacturing Company, TriMas Aerospace delivers innov
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom